Autopsy report · NCT03960151
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Cause of deathFunding or business
“Compound was sold by funder and development ceased.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Costantine Albany
- Sponsor type
- University, hospital or other
- Conditions
- Germ Cell Tumor
- Interventions
- Rolapitant; Palonosetron; Olanzapine; Dexamethasone
- Participants
- 0
Trials that died the same way
- A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
“Compound development discontinued” - Safety Study of Nebivolol for COPD Patients
“Funding was discontinued.” - Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
“Development discontinued” - CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
“The pharmaceutical funder pulled funding and no longer plans to develop the drug further.” - Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.
“The compound is no longer suitable for further clinical development due to a safety finding in a later phase program.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.